The MCP-1 A-2518G polymorphism increases the risk of Alzheimer’s disease: A case-control study

Bidirectional communication between brain and visceral white adipose tissue: Its potential impact on Alzheimer's disease

“…Genetic studies have proved that the A-2518G polymorphism of CCL2 was associated with an elevated risk for AD and increased serum concentration of CCL2. 130 The CSF level of CCL2 was positively correlated with the atrophy severity of medial temporal lobe structure and negatively correlated with Mini-Mental State Examination (MMSE) scores in AD patients. 131 The plasma concentration of CCL2 was higher in AD patients compared with that in MCI patients and controls, and was positively correlated with the severity of cognitive impairment.…”

The Role of CCL2/CCR2 Axis in Cerebral Ischemia-Reperfusion Injury and Treatment: From Animal Experiments to Clinical Trials

“…Due to the widespread expression of CCL2/CCR2 in the central nervous system, their expression levels are abnormally elevated when involved in the pathological process of nerve injuries such as stroke, brain trauma, subarachnoid hemorrhage, and psychosis [ 20 , 21 ]. Furthermore, the polymorphism and expression levels of CCL2/CCR2 are associated with the initiation and development process of some central nervous system disorders, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), multiple sclerosis (MS), and schizophrenia [ 22 , 23 , 24 , 25 , 26 , 27 , 28 ]. Additionally, CCL2 may be a useful biomarker for early antithrombotic therapy after ischemic stroke [ 29 ].…”